Elizabeth F Krakow, Michelle Brault, Corinne Summers, Tanya M Cunningham, Melinda A Biernacki, R Graeme Black, Kyle Blake Woodward, Nicole Vartanian, Sami B Kanaan, Albert C Yeh, Robson G Dossa, Merav Bar, Ryan D Cassaday, Ann Dahlberg, Brian G Till, Andrew E Denker, Cecilia C S Yeung, Ted A Gooley, David G Maloney, Stanley R Riddell, Philip D Greenberg, Aude G Chapuis, Evan W Newell, Scott N Furlan, Marie Bleakley
Relapse is the leading cause of death after allogeneic hematopoietic stem cell transplantation (HCT) for leukemia. T cells engineered by gene transfer to express T cell receptors (TCR; TCR-T) specific for hematopoietic-restricted minor histocompatibility (H) antigens may provide a potent selective anti-leukemic effect post-HCT. We conducted a phase I clinical trial employing a novel TCR-T product targeting the minor H antigen HA-1 to treat or consolidate treatment of persistent or recurrent leukemia and myeloid neoplasms...
April 29, 2024: Blood